Lajos Pusztai
Lajos Pusztai
Verified email at - Homepage
Cited by
Cited by
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
C Liedtke, C Mazouni, KR Hess, F André, A Tordai, JA Mejia, ...
Journal of clinical oncology 26 (8), 1275-1281, 2008
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier, CM Perou, WF Symmans, N Ibrahim, M Cristofanilli, ...
Clinical cancer research 11 (16), 5678-5685, 2005
The MicroArray Quality Control (MAQC) project shows inter-and intraplatform reproducibility of gene expression measurements.
L Shi, LH Reid, WD Jones, R Shippy, JA Warrington, SC Baker, PJ Collins, ...
Nature biotechnology 24 (9), 1151-1161, 2006
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
GM Frampton, A Fichtenholtz, GA Otto, K Wang, SR Downing, J He, ...
Nature biotechnology 31 (11), 1023-1031, 2013
Pembrolizumab for early triple-negative breast cancer
P Schmid, J Cortes, L Pusztai, H McArthur, S Kümmel, J Bergh, C Denkert, ...
New England Journal of Medicine 382 (9), 810-821, 2020
Gene-expression signatures in breast cancer
C Sotiriou, L Pusztai
New England Journal of Medicine 360 (8), 790-800, 2009
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy
WF Symmans, F Peintinger, C Hatzis, R Rajan, H Kuerer, V Valero, ...
Journal of Clinical Oncology 25 (28), 4414-4422, 2007
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
J Baselga, I Bradbury, H Eidtmann, S Di Cosimo, E De Azambuja, C Aura, ...
The Lancet 379 (9816), 633-640, 2012
Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study
R Nanda, LQM Chow, EC Dees, R Berger, S Gupta, R Geva, L Pusztai, ...
Journal of Clinical oncology 34 (21), 2460-2467, 2016
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in …
AU Buzdar, NK Ibrahim, D Francis, DJ Booser, ES Thomas, RL Theriault, ...
Journal of clinical oncology 23 (16), 3676-3685, 2005
The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine
JS Ross, EA Slodkowska, WF Symmans, L Pusztai, PM Ravdin, ...
The oncologist 14 (4), 320-368, 2009
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
K Stemke-Hale, AM Gonzalez-Angulo, A Lluch, RM Neve, WL Kuo, ...
Cancer research 68 (15), 6084-6091, 2008
Cancer heterogeneity: implications for targeted therapeutics
R Fisher, L Pusztai, C Swanton
British journal of cancer 108 (3), 479-485, 2013
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ...
Nature medicine 20 (11), 1301-1309, 2014
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
JS Ross, JA Fletcher, GP Linette, J Stec, E Clark, M Ayers, WF Symmans, ...
The oncologist 8 (4), 307-325, 2003
Gene expression profiling in breast cancer: classification, prognostication, and prediction
JS Reis-Filho, L Pusztai
The Lancet 378 (9805), 1812-1823, 2011
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
KR Hess, K Anderson, WF Symmans, V Valero, N Ibrahim, JA Mejia, ...
Journal of clinical oncology 24 (26), 4236-4244, 2006
Triple-negative breast cancer—current status and future directions
O Gluz, C Liedtke, N Gottschalk, L Pusztai, U Nitz, N Harbeck
Annals of Oncology 20 (12), 1913-1927, 2009
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2–overexpressing metastatic breast cancer
FJ Esteva, V Valero, D Booser, LT Guerra, JL Murray, L Pusztai, ...
Journal of Clinical Oncology 20 (7), 1800-1808, 2002
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.
L Shi, G Campbell, WD Jones, F Campagne, Z Wen, SJ Walker, Z Su, ...
Nature biotechnology 28 (8), 2010
The system can't perform the operation now. Try again later.
Articles 1–20